CO4480042A1 - Anticuerpo monoclonal anti alfa-v-integrinas - Google Patents

Anticuerpo monoclonal anti alfa-v-integrinas

Info

Publication number
CO4480042A1
CO4480042A1 CO95060553A CO95060553A CO4480042A1 CO 4480042 A1 CO4480042 A1 CO 4480042A1 CO 95060553 A CO95060553 A CO 95060553A CO 95060553 A CO95060553 A CO 95060553A CO 4480042 A1 CO4480042 A1 CO 4480042A1
Authority
CO
Colombia
Prior art keywords
monoclonal antibody
integrine
integrines
vbeta3
antibody
Prior art date
Application number
CO95060553A
Other languages
English (en)
Inventor
Francesc Mitjans
Jaume Piulats
Elisabet Rosell
Adan Jaume
Simon Goodman
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4480042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO4480042A1 publication Critical patent/CO4480042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. ANTICUERPO MONOCLONAL QUE TIENE LAS PROPIEDA- DES SIGUIENTES: - REACCIONA SOLAMENTE CON LA CADENA @V DE LAS IN- TEGRINAS @V HUMANAS; - BLOQUEA LA UNION AL SUSTRATO DE INTEGRINA DE LA CELULA PORTADORA DE LA INTEGRINA @V; - IMPULSA LA REVERSION DE LA INTERACCION ESTABLE- CIDA PARA LA MATRIZ CELULAR, CAUSADA POR LAS INTE- GRINAS @V; - BLOQUEA EL DESARROLLO DE TUMORES, Y - NO EVIDENCIA ACCION CITOTOXICA. 6. LINEA DE CELULAS DE HIBRIDOMA QUE TIENE LA DE- NOMINACION DE 272-17E6 Y ESTA DEPOSITADA CON EL NUMERO DE ACCESO DSM ACC2160, CAPAZ DE PRODUCIR UN ANTICUERPO MONOCLONAL DE LAS REIVINDICACIONES 1 A 4. 8. SECUENCIA DE AMINOACIDOS QUE COMPRENDE LA SE- CUENCIA REPRESENTADA EN LA FIGURA 17a. 9. SECUENCIA DE AMINOACIDOS QUE COMPRENDE LA SE- CUENCIA REPRESENTADA EN LA FIGURA 17b. 17. PROCEDIMIENTO PARA PRODUCIR UN ANTICUERPO MO- NOCLONAL SEGUN LAS REIVINDICACIONES 1 A 4, POR IN- MUNIZACION DE UN RATON CON INTEGRINA @VBETA3 PURI- FICADA; SELECCION DE CLONES QUE SE UNEN AL RECEPTOR DE @VBETA3 RESPECTIVO, PURIFICADO, MEDIANTE ELISA, Y OBTENCION POR TECNICAS CLASICAS DE UNA LINEA DE CELULAS, ESPECIFICA, QUE PRODUCE DICHO ANTICUERPO.
CO95060553A 1994-12-20 1995-12-20 Anticuerpo monoclonal anti alfa-v-integrinas CO4480042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (1)

Publication Number Publication Date
CO4480042A1 true CO4480042A1 (es) 1997-07-09

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95060553A CO4480042A1 (es) 1994-12-20 1995-12-20 Anticuerpo monoclonal anti alfa-v-integrinas

Country Status (26)

Country Link
US (1) US5985278A (es)
EP (1) EP0719859B1 (es)
JP (1) JP3898245B2 (es)
KR (1) KR100450368B1 (es)
CN (1) CN1117763C (es)
AR (1) AR001778A1 (es)
AT (1) ATE244306T1 (es)
AU (1) AU710234B2 (es)
BR (1) BR9505980B1 (es)
CA (1) CA2165573C (es)
CO (1) CO4480042A1 (es)
CZ (1) CZ290477B6 (es)
DE (1) DE69531187T2 (es)
DK (1) DK0719859T3 (es)
ES (1) ES2202336T3 (es)
FI (1) FI118536B (es)
HU (1) HU221061B1 (es)
NO (1) NO321186B1 (es)
PL (1) PL182961B1 (es)
PT (1) PT719859E (es)
RU (1) RU2205223C2 (es)
SI (1) SI0719859T1 (es)
SK (1) SK284932B6 (es)
TR (1) TR199501614A2 (es)
UA (1) UA40621C2 (es)
ZA (1) ZA9510806B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
EE04752B1 (et) * 1997-08-08 2006-12-15 The Regents Of The University Of California Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
AU2716399A (en) * 1998-01-23 1999-08-09 Merck Patent Gmbh Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbeta6-integrin attachment to fibronectin
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20020168360A1 (en) * 2001-03-02 2002-11-14 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
WO2003006893A2 (en) * 2001-07-09 2003-01-23 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
CN102924598B (zh) * 2002-03-13 2014-12-31 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
CA2481922A1 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
WO2004091510A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2008060645A2 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
US20090175784A1 (en) 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
BRPI0815567B8 (pt) * 2007-07-17 2021-05-25 Merck Patent Gessellschaft Mit Beschraenkter Haftung anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
EP2706358A3 (en) 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
CA2753988C (en) 2009-03-25 2017-04-25 Genentech, Inc. Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
CA2780773A1 (en) 2009-11-13 2011-05-19 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
CA2790488C (en) * 2010-02-18 2018-09-25 The Regents Of The University Of California Integrin .alpha.v.beta.8 neutrilizing antibody
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
EP3415162A1 (en) 2011-02-11 2018-12-19 Merck Patent GmbH Anti-alpha-v integrin antibody for the treatment of prostate cancer
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
NZ720736A (en) 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
SG11201702135PA (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
MX2017003406A (es) 2014-09-17 2017-06-19 Merck Patent Gmbh Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
CA2990076A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
PE20180452A1 (es) 2015-06-23 2018-03-05 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
AU2017380871A1 (en) 2016-12-21 2019-07-11 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
WO2020079209A1 (en) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
BR112021020116A2 (pt) * 2019-04-08 2021-12-07 Biogen Ma Inc Anticorpos anti-integrina e usos dos mesmos
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633945B1 (en) * 1992-04-03 1998-12-30 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
DK0719859T3 (da) 2003-10-20
BR9505980B1 (pt) 2010-02-23
NO955167L (no) 1996-06-21
JPH08231597A (ja) 1996-09-10
US5985278A (en) 1999-11-16
KR960022562A (ko) 1996-07-18
ES2202336T3 (es) 2004-04-01
TR199501614A2 (tr) 1996-07-21
BR9505980A (pt) 1997-12-23
EP0719859B1 (en) 2003-07-02
CZ290477B6 (cs) 2002-07-17
RU2205223C2 (ru) 2003-05-27
HU9503638D0 (en) 1996-02-28
EP0719859A1 (en) 1996-07-03
DE69531187D1 (de) 2003-08-07
UA40621C2 (uk) 2001-08-15
HUT74828A (en) 1997-02-28
SK284932B6 (sk) 2006-02-02
JP3898245B2 (ja) 2007-03-28
FI956112A0 (fi) 1995-12-19
ZA9510806B (en) 1996-05-30
PL182961B1 (pl) 2002-05-31
ATE244306T1 (de) 2003-07-15
CN1117763C (zh) 2003-08-13
CA2165573A1 (en) 1996-06-21
SI0719859T1 (en) 2003-12-31
CA2165573C (en) 2011-03-29
PT719859E (pt) 2003-11-28
AR001778A1 (es) 1997-12-10
FI118536B (fi) 2007-12-14
CZ328895A3 (en) 1996-09-11
SK159295A3 (en) 1996-07-03
KR100450368B1 (ko) 2005-01-31
NO321186B1 (no) 2006-04-03
PL311926A1 (en) 1996-06-24
FI956112A (fi) 1996-06-21
NO955167D0 (no) 1995-12-19
HU221061B1 (hu) 2002-07-29
DE69531187T2 (de) 2004-04-22
AU4042195A (en) 1996-06-27
CN1139115A (zh) 1997-01-01
AU710234B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
CO4480042A1 (es) Anticuerpo monoclonal anti alfa-v-integrinas
ES2150573T3 (es) Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
Oursler et al. Identification of osteoclast-specific monoclonal antibodies.
PT865448E (pt) Apoptose induzida pelo anticorpo monoclonal anti-her2
ATE58554T1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
EP0330506A3 (en) Vla proteins
ES2061736T3 (es) Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen.
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ATE94205T1 (de) Monoklonale antikoerper gegen melanoma-assoziierte antigene, hybridzellinien, die diese antikoerper produzieren, und ihre verwendung.
DK0765343T3 (da) Monoklonale antistoffer imod CD44v6
DE68924773D1 (de) Monoklonale antikörper gegen den bereich der leichten kette von menschlichem faktor xii sowie methoden zu deren herstellung und verwendung.
Kodama et al. Monoclonal antibodies to bovine collagenase inhibitor
CA1251747A (en) MONOCLONAL ANTIBODIES AGAINST CYTOPLASMIC ANTIGENS OF CANDIDA ALBICANS AND METHOD OF PREPARATION
ES2149244T3 (es) Procedimientos para producir proteina c.
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
DK0876610T3 (da) Fremgangsmåde og anvendelse af polypeptid i sædcelle-æg-binding til at foröge eller mindske fertilitet
NO883854L (no) Monoklonalt antistoff og fremgangsmaate for dets fremstilling.
AR241656A1 (es) Una linea celular producida por un tecnica de hibridoma y un anticuerpo monoclonal.
Koyama et al. Identification of sperm antigenic determinants with phylogenetically diverse and limited distribution using monoclonal antibodies
Nolan et al. A monoclonal antibody to dopamine β-monooxygenase: detection of biosynthetic intermediates
Russinova et al. Localization and partial characterization of a rat ovarian granulose cell protein with a monoclonal antibody
Shibier et al. An immunisation protocol which enhances the frequency of antigen-specific monoclonal antibody production
Cohen Structure of antibodies
CO5060487A1 (es) Anticuerpos anti-idiotipos contra anticuerpos que reconocen gangliosidos portadores de acido sialico n-glicolilado y com posiciones que los contienen
WO1987007147A1 (en) Method for producing monoclonal antibodies to an immunogenic antibody-antigen conjunction